Lipid Nanoparticles as a Shuttle for Anti-Adipogenic miRNAs to Human Adipocytes.
adipogenesis
automated quantitative image analysis
lipid nanoparticles
microRNA
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
19 Jul 2023
19 Jul 2023
Historique:
received:
15
06
2023
revised:
12
07
2023
accepted:
16
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Obesity and type 2 diabetes are major health burdens for which no effective therapy is available today. One treatment strategy could be to balance the metabolic functions of adipose tissue by regulating gene expressions using miRNAs. Here, we have loaded two anti-adipogenic miRNAs (miR26a and miR27a) into a pegylated lipid nanoparticle (PEG-LNP) formulation by a single-step microfluidic-assisted synthesis step. For the miRNA-loaded LNPs, the following system properties were determined: particle size, zeta potential, miRNA complexation efficiency, and cytotoxicity. We have used a human preadipocyte cell line to address the transfection efficiency and biological effects of the miRNA candidates at the gene and protein level. Our findings revealed that the upregulation of miR27a in preadipocytes inhibits adipogenesis by the downregulation of PPARγ and the reduction of lipid droplet formation. In contrast, miR26a transfection in adipocytes induced white adipocyte browning detected as the upregulation of uncoupling protein 1 (UCP1) as a marker of non-shivering thermogenesis. We conclude that the selective delivery of miRNAs by PEG-LNPs to adipocytes could offer new perspectives for the treatment of obesity and related metabolic diseases.
Identifiants
pubmed: 37514169
pii: pharmaceutics15071983
doi: 10.3390/pharmaceutics15071983
pmc: PMC10384627
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Blood. 2012 Feb 9;119(6):1607-16
pubmed: 22184411
Int J Nanomedicine. 2019 Sep 25;14:7795-7808
pubmed: 31576124
J Control Release. 2021 Jan 10;329:665-675
pubmed: 33038450
Am J Physiol Endocrinol Metab. 2010 Jun;298(6):E1244-53
pubmed: 20354155
Mol Metab. 2020 Jun;36:100964
pubmed: 32248079
Nat Rev Neurol. 2018 Oct;14(10):570
pubmed: 30158559
Nat Rev Endocrinol. 2019 May;15(5):288-298
pubmed: 30814686
Nat Rev Drug Discov. 2016 Sep;15(9):639-660
pubmed: 27256476
Int J Mol Sci. 2019 Oct 12;20(20):
pubmed: 31614705
Pharmacol Res. 2021 Jul;169:105649
pubmed: 33962014
Int J Obes (Lond). 2022 Nov;46(11):1939-1947
pubmed: 35986215
Biochem Biophys Res Commun. 2010 Feb 12;392(3):323-8
pubmed: 20060380
Adv Drug Deliv Rev. 2021 Mar;170:83-112
pubmed: 33400957
Oncol Lett. 2011 Nov;2(6):1019-1023
pubmed: 22848262
Am J Physiol Cell Physiol. 2000 Sep;279(3):C670-81
pubmed: 10942717
J Endocrinol. 2019 May 10;241(3):R97-R109
pubmed: 31144796
Nat Rev Drug Discov. 2016 Jun;15(6):405-24
pubmed: 26965204
Chem Phys Lipids. 2020 Jan;226:104837
pubmed: 31689410
Cell. 2012 Jul 20;150(2):366-76
pubmed: 22796012
Endocrinology. 2008 Dec;149(12):6053-64
pubmed: 18687778
Angew Chem Int Ed Engl. 2012 Aug 20;51(34):8529-33
pubmed: 22782619
RNA. 2006 Sep;12(9):1626-32
pubmed: 16870994
Commun Biol. 2021 Aug 11;4(1):956
pubmed: 34381159
Cells. 2020 Nov 16;9(11):
pubmed: 33207733
Obes Facts. 2008;1(4):184-9
pubmed: 20054179
Microsc Microanal. 2021 Oct 18;:1-12
pubmed: 34851247
Nano Lett. 2021 Jul 14;21(13):5671-5680
pubmed: 34189917
Methods Protoc. 2021 Jan 20;4(1):
pubmed: 33498244
Stem Cells. 2014 Jun;32(6):1578-90
pubmed: 24375761
Nat Med. 2013 Oct;19(10):1338-44
pubmed: 23995282
Front Endocrinol (Lausanne). 2020 Oct 06;11:563816
pubmed: 33123088
Acc Chem Res. 2019 Sep 17;52(9):2435-2444
pubmed: 31397996
PLoS Biol. 2018 Jul 3;16(7):e2005970
pubmed: 29969450
Comput Med Imaging Graph. 2015 Dec;46 Pt 2:197-208
pubmed: 26362074
J Adv Res. 2020 Aug 29;28:127-138
pubmed: 33364050
Histochem Cell Biol. 2001 Jul;116(1):63-8
pubmed: 11479724
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jan;1864(1):29-36
pubmed: 29758288
Open Biol. 2020 Dec;10(12):200291
pubmed: 33292104
Front Cell Dev Biol. 2018 Apr 04;6:33
pubmed: 29670879
Biochem Biophys Res Commun. 2009 Dec 11;390(2):247-51
pubmed: 19800867
Adv Drug Deliv Rev. 2020;154-155:102-122
pubmed: 32650041
J Biol Chem. 2010 Mar 5;285(10):7153-64
pubmed: 20028987
Br J Pharmacol. 2022 Oct 17;:
pubmed: 36250252
Front Endocrinol (Lausanne). 2018 Aug 07;9:447
pubmed: 30131768
Curr Mol Med. 2011 Jun;11(4):304-16
pubmed: 21506921
Mol Cell. 1999 Oct;4(4):611-7
pubmed: 10549292
Nat Cell Biol. 2013 Jun;15(6):659-67
pubmed: 23624403
Horm Mol Biol Clin Investig. 2017 Jun 23;31(2):
pubmed: 28672737
Anal Biochem. 2020 Oct 1;606:113828
pubmed: 32745542
FEBS J. 2009 Apr;276(8):2348-58
pubmed: 19348006
Nature. 2006 Dec 14;444(7121):847-53
pubmed: 17167472
Front Physiol. 2018 Nov 23;9:1672
pubmed: 30532712
J Am Chem Soc. 2023 Feb 1;145(4):2294-2304
pubmed: 36652629
Handb Exp Pharmacol. 2019;251:215-237
pubmed: 30478736
Biology (Basel). 2022 Nov 13;11(11):
pubmed: 36421371
Adipocyte. 2021 Dec;10(1):48-65
pubmed: 33403891
Diabetes. 2007 Oct;56(10):2541-6
pubmed: 17646208
Orphanet J Rare Dis. 2014 Sep 20;9:138
pubmed: 25238977
J Control Release. 2016 Aug 10;235:337-351
pubmed: 27297779
Signal Transduct Target Ther. 2020 Jun 19;5(1):101
pubmed: 32561705
Pharmacoeconomics. 2015 Jul;33(7):673-89
pubmed: 25471927
Adv Drug Deliv Rev. 2022 Feb;181:114110
pubmed: 34995679
Clin Sci (Lond). 2019 Jan 3;133(1):23-40
pubmed: 30606812